Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy
Authors:
Open Access
- 10 April 2014
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 110 (9) , 2209-2216
Abstract
Although Trastuzumab has improved survival of HER2+ breast cancer patients, resistance to the agent pre-exists or develops through the course of therapy. Here we show that a specific metabolism and autophagy-related cancer cell phenotype relates to resistance of HER2+ breast cancer to Trastuzumab and chemotherapy. Twenty-eight patients with locally advanced primary breast cancer were prospectively scheduled to received one cycle of Trastuzumab followed by a new biopsy on day 21, followed by taxol/Trastuzumab chemotherapy for four cycles before surgery. FDG PET/CT scan was used to monitor tumour response. Tissue samples were immunohistochemically analysed for metabolism and autophagy markers. In pre-Trastuzumab biopsies, the LC3A+/HER2+ cell population was correlated with HIF1α expression (P=0.01), while GLUT1 and LC3B expression were correlated with Ki67 proliferation index (P=0.01 and P=0.01, respectively). FDG PET tumour dimensions before therapy were correlated with LC3B expression (P=0.005). Administration of Trastuzumab significantly reduced clinical and PET-detected tumour dimensions (P<0.01). An inverse association of tumour response with the percentage of cells expressing HIF1α at baseline was documented (P=0.01). Administration of Trastuzumab resulted in a decrease of the proliferation index (P=0.004), GLUT1 (P=0.04) and HER2 (P=0.01) expression. In contrast, the percentage of LC3A+/HER2+ cells was increased (P=0.01). High baseline HIF1α expression was the only parameter associated with poorer pathological response to preoperative chemotherapy (P=0.001). As the HER2+/LC3A+ phenotype, which often overexpresses HIF1α, is a major subpopulation increasing after therapy with Trastuzumab, LC3A- and HIF1α-targeting therapies should be investigated for the augmentation of anti-HER2 therapy efficacy.Keywords
This publication has 25 references indexed in Scilit:
- LC3 immunostaining pitfallsHistopathology, 2013
- Overexpression of LC3A autophagy protein in follicular and diffuse large B-cell lymphomasHematology/Oncology and Stem Cell Therapy, 2013
- Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatmentOncotarget, 2012
- Autophagy patterns and prognosis in uveal melanomasLaboratory Investigation, 2011
- HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapiesExpert Review of Anticancer Therapy, 2011
- Prognostic relevance of light chain 3 (LC3A) autophagy patterns in colorectal adenocarcinomasJournal of Clinical Pathology, 2010
- Trastuzumab‐based neoadjuvant therapy in patients with HER2‐positive breast cancerCancer, 2010
- Hypoxia-Induced Autophagy Is Mediated through Hypoxia-Inducible Factor Induction of BNIP3 and BNIP3L via Their BH3 DomainsMolecular and Cellular Biology, 2009
- Hypoxia-Inducible Factor-2α (HIF-2α) Induces Angiogenesis in Breast CarcinomasApplied Immunohistochemistry & Molecular Morphology, 2006
- Levels of hypoxia‐inducible factor‐1α independently predict prognosis in patients with lymph node negative breast carcinomaCancer, 2003